Drug intelligence / Profile preview

Q003

Development stage: Preclinical
Lead developer: Quodria
Modality: Small Molecules
Administration: Topical

Overview

Q003 is a non-steroidal topical small molecule inhibitor of galectin-3 being developed by Quodria Ltd for the treatment of psoriasis. Galectin-3 is a protein known to have pro-inflammatory and pro-fibrotic effects, and its inhibition is intended to manage the inflammatory processes underlying psoriasis. The drug is designed for use as a standalone therapy or in combination with other psoriasis treatments. Q003 utilizes the same galectin-3 targeting mechanism established in Quodria's Q001 program for atopic dermatitis.

Targets

LGALS3 (Galectin-3)

Beyond the preview

Go deeper on Q003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q003.

Explore the full profile